Latest Conference Coverage

Erenumab Improves Daily Functioning and Quality of Life

The Novartis agent showed significant reduction of migraine days in both the real-world TELESCOPE and PERISCOPE studies in patients with migraine.

Perampanel May Improve Insomnia in Patients With Epilepsy and Anxiety

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.

Mary Rensel, MD: Transitioning to Shared Medical Appointments

The director of Pediatric MS and Wellness programming at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine discussed the harsh realities of patients adopting a new treatment method.

Le Hua, MD: Siponimod in Secondary Progressive Multiple Sclerosis

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed what can currently be surmised about siponimod’s effect in treating patients with SPMS.

Le Hua, MD: Subanalysis of the EXPAND Study of Siponimod in SPMS

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.

Le Hua, MD: Considering Age in Multiple Sclerosis Treatment

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the need to take age into consideration when managing a patient with MS, and how the thinking about the disease and age has shifted.

Le Hua, MD: Disease Duration and Age in MS

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed the current thinking about the challenges of addressing multiple sclerosis in older patients.

Robert Glanzman, MD: Overview of CNM-Au8

The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.

Quick Access to EVT Centers for Acute Stroke Is Greatly Limited, Study Suggests

Data suggests that access to endovascular thrombectomy centers within 15 minutes is limited to less than one-fifth of the population, pointing to a need for improved access and bypass methodologies.

Mary Rensel, MD: Integrating Shared Medical Appointments in MS

The director of Pediatric MS and Wellness at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine describes her study on shared medical appointments and the intricacies of integrating them into the common care realm.

Carrie Hersh, DO, MSc: Measuring Progressive Multiple Sclerosis

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, discussed the challenges of current measurements and the need to adjust the reading of progressive MS.

Tanuja Chitnis, MD: Consequences of Incomplete Recovery in MS

The director of the Partners Pediatric MS Center at Massachusetts General Hospital for Children provided insight on the consequences of incomplete relapse recovery in multiple sclerosis.

Carrie Hersh, DO, MSc: Addressing Progressive Disease in MS

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, spoke to the importance of preventing progression in MS and treating the non-inflammatory aspects of the disease.

Augusto Miravalle, MD: How Cladribine Sets Itself Apart in MS

The associate professor in the department of neurology at the University of Colorado and neurologist at Advanced Neurology of Colorado discussed the advantages of cladribine and details of the ongoing CLICK-MS study.

Cladribine Effectively Reduces Risk of Secondary Progressive Multiple Sclerosis

Similar effects were observed for each proxy SMPS component when compared with placebo.

Endovascular Therapy Displays Similar Outcomes to Intravenous Thrombolysis

When performed by itself, endovascular therapy had greater rates of intracranial hemorrhage compared to a combination of both endovascular therapy and intravenous thrombolysis.

CNM-Au8 Improves Visual Acuity in Patients With MS With Optic Neuropathy

This included the first 34 participants from the VISIONARY-MS study, which is currently ongoing with the orally delivered suspension of clean-surfaced, faceted gold nanocrystals.

Cladribine Shows Durable Efficacy in Relapsing Multiple Sclerosis

Data from the CLARITY extension trial suggest that the durability of treatment with cladribine extended beyond 24 months in those with relapsing-remitting multiple sclerosis.

Incomplete Recovery From MS Relapse May Contribute to Long-Term Disability

Recovery status may be a useful tool to predict long-term outcomes in patients with relapsing forms of multiple sclerosis.

Ofatumumab Nearly Clears B-Cell Activity With At-Home Dosing

The investigational MS therapy is currently under review with the FDA, with a PDUFA date set for June 2020.

Earlier Ocrelizumab Treatment in MS Has Positive Long-term Impact

Compared with patients who initially received interferon treatment, those given ocrelizumab had superior disability progression after a 6-year follow-up.

Siponimod Significantly Slows MS Disability Progression in Patients With Shorter Disease Duration

Patients with a disease duration of <16 years demonstrated a significantly greater reduction in risk for confirmed disability progression (CDP) at 3 and 6 months.

Early Administration of Tranexamic Acid May Reduce Intracerebral Hemorrhage in Stroke

Phase 2 STOP-AUST data suggest that the antifibrinolytic agent may be able to reduce ICH in spot sign positive patients with stroke when administered within 2 to 3 hours of onset, warranting further study.

Low-Dose Tenecteplase Ideal for Stroke Treatment

New study data from ISC 2020 suggest that patients with stroke can be effectively treated with tenecteplase at a lower dose of 0.25 mg/kg, reducing the need for mechanical clot removal.

Functional Outcomes Improved by Mobile Stroke Units

Stroke patients experienced higher rates of thrombolysis as well as faster alarm to treatment times when mobile stroke units were present.

Lower LDL-C Target May Help Prevent Vascular Events Following Ischemic Stroke

The composite primary end point of the study occurred in 9.6% of patients in the lower-target LDL-C group compared with 12.9% in the higher target group.

Novel Stroke Treatment Nerinetide Falls Short in Phase 3

Despite missing the primary end point, data from a subset of patients suggest that the novel peptide may be beneficial in those who have not received alteplase.

Portable MRI Safe and Functional for Bedside Stroke Imaging

Despite the conventional need for patients to travel to MRI devices, the use of a point-of-care, portable scanner has proven to be a feasible method of acquiring clinically useful images.

Poststroke Seizures Associated With Increased Risk for Functional Disability, Death

Patients 65 and under were more likely to develop seizures following a stroke than older patients.

Shingles Vaccine Linked to Lower Risk of Stroke

The beneficial impact on stroke risk appeared to be greater in patients age 79 and younger than in the older patients examined.